MBTPS1 and multiple sclerosis: According to researchers, new doors for treatment are opened because of Sphingosine-1-phosphate modulators that are approved for the treatment of different immune-mediated conditions.[26,27] Clinical trials that targeted S1P receptors for inflammatory disorders were successful, and as a result, the non-selective S1P modulator fingolimod was approved for relapsing forms of multiple sclerosis.